Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 15/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | C1S | P09871 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587824 | 0.85 | EIF4E (0.39) | EIF4ETHRBC1SGFER | |
| SCHEMBL1447033 | 0.84 | EIF4E (0.46) | EIF4ETHRBKDM4EMAPTC1S | |
| SCHEMBL1447141 | 0.83 | THRB (0.41) | EIF4ETHRBC1SGFER | |
| SCHEMBL3593837 | 0.82 | COMT (0.39) | KDM4EMAPTMAOAMAOB | |
| SCHEMBL3586419 | 0.82 | MAPT (0.39) | THRBKDM4EMAPTMAOAMAOB | |
| SCHEMBL3576813 | 0.81 | EIF4E (0.44) | EIF4ETHRBKDM4EMAPTGFER | |
| SCHEMBL3583841 | 0.81 | MAPT (0.39) | THRBKDM4EMAPTMAOAMAOB | |
| SCHEMBL3588938 | 0.81 | MAPT (0.37) | KDM4EMAPTMAOAMAOB | |
| SCHEMBL3576471 | 0.81 | EIF4E (0.46) | EIF4ETHRBGFER | |
| SCHEMBL3581810 | 0.80 | MAPT (0.38) | KDM4EMAPTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | disclosed |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2014-01-23 | — | — | US | disclosed |
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | disclosed |
| EP-2617713-A1 | New Pharmaceutical Compounds | BIAL - Portela & Ca., S.A. (PT) | 2013-07-24 | — | — | EP | disclosed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | disclosed |
| EP-2027091-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - Portela & Ca., S.A. (PT) | 2009-02-25 | — | — | EP | disclosed |
| CN-101248064-A | Nitrocatechol derivatives as COMT inhibitors | PORTELA & CA SA (PT) | 2008-08-20 | — | — | CN | disclosed |
| WO-2007117165-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | EIF4E 4154/4885THRB 3587/4885KDM4E 3648/4885 |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | PMP22, CNR2, OPRL1 | EIF4E 4154/4885THRB 3587/4885KDM4E 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.